Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma.
Iida K, Naiki T, Etani T, Nagai T, Sugiyama Y, Isobe T, Aoki M, Nozaki S, Noda Y, Shimizu N, Tomiyama N, Gonda M, Kamiya H, Kubota H, Nakane A, Ando R, Kawai N, Yasui T.
Iida K, et al. Among authors: nozaki s.
Sci Rep. 2024 Jan 30;14(1):2520. doi: 10.1038/s41598-024-53158-1.
Sci Rep. 2024.
PMID: 38291115
Free PMC article.